Biomarin Pharmaceutical's EBITDA per Share for the
three
months ended in Dec. 2023 was $0.27.
During the past 12 months, Biomarin Pharmaceutical's average EBITDA Per Share Growth Rate was 14.40% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 54.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Biomarin Pharmaceutical was 99.50% per year. The lowest was -438.30% per year. And the median was 0.45% per year.
Competitive Comparison
For the Biotechnology subindustry, Biomarin Pharmaceutical's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomarin Pharmaceutical 5-Year EBITDA Growth Rate Distribution
For the Biotechnology industry and Healthcare sector, Biomarin Pharmaceutical's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Biomarin Pharmaceutical's 5-Year EBITDA Growth Rate falls into.
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Biomarin Pharmaceutical 5-Year EBITDA Growth Rate Related Terms
Thank you for viewing the detailed overview of Biomarin Pharmaceutical's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Biomarin Pharmaceutical (Biomarin Pharmaceutical) Business Description
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU (in addition to long-standing U.S. rights, BioMarin has reacquired international rights for Kuvan and Palynziq from Merck KGaA). Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the U.S. in 2023.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
BMRN has been successfully added to your